Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
127,672,444
-
Total 13F shares
-
80,984,271
-
Share change
-
+11,988,637
-
Total reported value
-
$3,828,241,808
-
Put/Call ratio
-
44%
-
Price per share
-
$47.28
-
Number of holders
-
182
-
Value change
-
+$611,992,647
-
Number of buys
-
106
-
Number of sells
-
84
Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q4 2021
As of 31 Dec 2021,
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) was held by
182 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
80,984,271 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, Avoro Capital Advisors LLC, VANGUARD GROUP INC, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, EcoR1 Capital, LLC, STATE STREET CORP, Octagon Capital Advisors LP, RTW INVESTMENTS, LP, and JENNISON ASSOCIATES LLC.
This page lists
183
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.